

# Physician Advisers Urge CMS to Back Pay Revamp

BY JOEL B. FINKELSTEIN  
Contributing Writer

WASHINGTON — The failure to address low physician pay and looming reimbursement cuts in the Medicare program is starting to affect beneficiaries, members of Medicare's Practicing Physicians Advisory Council said at their recent meeting.

PPAC member Dr. Vincent J. Bufalino, a cardiologist from Naperville, Ill., offered an example to the council. "We have in

our community the beginnings of physicians walking away from Medicare. Four of the busiest internists in town have said 'No' and ripped up their [Medicare] agreement," Dr. Bufalino said.

Although the Centers for Medicare and Medicaid Services tracks physician participation, such trends might not reveal the whole picture, he added. Half of the physicians in Dr. Bufalino's community are no longer accepting new Medicare patients, he said. Although the CMS still counts them as

participating in the program, the trend is having a profound effect on beneficiaries' access to physician services.

"We don't think that participation rates, assignment rates, really reflect what is going on," Dr. Bufalino told CMS Deputy Administrator Leslie Norwalk.

The CMS has to rely on the numbers gathered by physician groups, she responded. "I suspect that the best way to go about this is probably at the state level where you would ask your state medical so-

ciety to survey members and let us know what it is that you see. ... It may help inform the debate," Ms. Norwalk suggested, noting that administration officials are barred from telling people to lobby Congress.

Lawmakers will have to be the ones to make changes to the current mechanism for updating physician payments. Based on the sustained growth rate (SGR) formula, mandated by the Balanced Budget Act of 1997, physicians are currently slated for a 5.1% cut in reimbursement starting Jan. 1. In past years, Congress has averted cuts or given doctors a small raise.

PPAC members urged CMS officials to use what influence they have to encourage lawmakers to do so again based on the recommendation from the Medicare Payment Advisory Commission that physician pay be increased by 2.8% in 2007.

"If you look at the data from 2001 to 2007, physicians' costs are up 18%, yet Medicare payments are down 5%. ... Only physicians are subject to arbitrary spending cuts. Hospitals have had a 3.7% update; nursing homes, a 3.1%; [and] Medicare Advantage now gets 111% of the fee-for-service rate and is slated for another 4.8% increase," said PPAC member M. LeRoy Sprang, an ob.gyn. from Evanston, Ill.

Quality is an important part of the equation, said Dr. Tom Valuck, a medical officer at the CMS Center for Medicare Management. "We're not talking about arbitrary cost cutting for necessary services. We're talking about taking waste out of the system."

PPAC members asked CMS officials to keep in mind that as physicians strive to improve quality and lower costs, they should also be recognized for savings that may show up elsewhere, such as in reduced hospital spending due to more preventive screening or disease management services provided in doctors' offices. ■

## ParaGard<sup>®</sup> T 380A<sup>®</sup> intrauterine copper contraceptive

Brief Summary

(See package brochure for full prescribing information)

Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

ParaGard<sup>®</sup> T 380A Intrauterine Copper Contraceptive should be placed and removed only by healthcare professionals who are experienced with these procedures.

### INDICATIONS AND USAGE

ParaGard<sup>®</sup> is indicated for intrauterine contraception for up to 10 years. The pregnancy rate in clinical studies has been less than 1 pregnancy per 100 women each year.

### CONTRAINDICATIONS

ParaGard<sup>®</sup> should not be placed when one or more of the following conditions exist:

1. Pregnancy or suspicion of pregnancy
2. Abnormalities of the uterus resulting in distortion of the uterine cavity
3. Acute pelvic inflammatory disease, or current behavior suggesting a high risk for pelvic inflammatory disease
4. Postpartum endometritis or postabortal endometritis in the past 3 months
5. Known or suspected uterine or cervical malignancy
6. Genital bleeding of unknown etiology
7. Mucopurulent cervicitis
8. Wilson's disease
9. Allergy to any component of ParaGard<sup>®</sup>
10. A previously placed IUD that has not been removed

### WARNINGS

#### 1. Intrauterine Pregnancy

If intrauterine pregnancy occurs with ParaGard<sup>®</sup> in place and the string is visible, ParaGard<sup>®</sup> should be removed because of the risk of spontaneous abortion, premature delivery, sepsis, septic shock, and, rarely, death. Removal may be followed by pregnancy loss.

If the string is not visible, and the woman decides to continue her pregnancy, check if the ParaGard<sup>®</sup> is in her uterus (for example, by ultrasound). If ParaGard<sup>®</sup> is in her uterus, warn her that there is an increased risk of spontaneous abortion and sepsis, septic shock, and rarely, death. In addition, the risk of premature labor and delivery is increased.

Human data about risk of birth defects from copper exposure are limited. However, studies have not detected a pattern of abnormalities, and published reports do not suggest a risk that is higher than the baseline risk for birth defects.

#### 2. Ectopic Pregnancy

Women who become pregnant while using ParaGard<sup>®</sup> should be evaluated for ectopic pregnancy. A pregnancy that occurs with ParaGard<sup>®</sup> in place is more likely to be ectopic than a pregnancy in the general population. However, because ParaGard<sup>®</sup> prevents most pregnancies, women who use ParaGard<sup>®</sup> have a lower risk of an ectopic pregnancy than sexually active women who do not use any contraception.

#### 3. Pelvic Infection

Although pelvic inflammatory disease (PID) in women using IUDs is uncommon, IUDs may be associated with an increased relative risk of PID compared to other forms of contraception and to no contraception. The highest incidence of PID occurs within 20 days following insertion. Therefore, the visit following the first post-insertion menstrual period is an opportunity to assess the patient for infection, as well as to check that the IUD is in place. Since pelvic infection is most frequently associated with sexually transmitted organisms, IUDs are not recommended for women at high risk for sexual infection. Prophylactic antibiotics at the time of insertion do not appear to lower the incidence of PID.

PID can have serious consequences, such as tubal damage (leading to ectopic pregnancy or infertility), hysterectomy, sepsis, and, rarely, death. It is therefore important to promptly assess and treat any woman who develops signs or symptoms of PID.

Guidelines for treatment of PID are available from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia at www.cdc.gov or 1-800-311-3435. Antibiotics are the mainstay of therapy. Most healthcare professionals also remove the IUD.

The significance of actinomyces-like organisms on Papanicolaou smear in an asymptomatic IUD-user is unknown, and so this finding alone does not always require IUD removal and treatment. However, because pelvic actinomyces is a serious infection, a woman who has symptoms of pelvic infection possibly due to actinomyces should be treated and have her IUD removed.

#### 4. Immunosuppression

Women with AIDS should not have IUDs inserted unless they are clinically stable on antiretroviral therapy. Limited data suggest that asymptomatic women infected with human immunodeficiency virus may use intrauterine devices. Little is known about the use of IUDs in women who have illnesses causing serious immunosuppression. Therefore these women should be carefully monitored for infection if they choose to use an IUD. The risk of pregnancy should be weighed against the theoretical risk of infection.

#### 5. Embedment

Partial penetration or embedment of ParaGard<sup>®</sup> in the myometrium can make removal difficult. In some cases, surgical removal may be necessary.

#### 6. Perforation

Partial or total perforation of the uterine wall or cervix may occur rarely during placement, although it may not be detected until later. Spontaneous migration has also been reported. If perforation does occur, remove ParaGard<sup>®</sup> promptly, since the copper can lead to intraperitoneal adhesions. Intestinal perforation, intestinal obstruction, and/or damage to adjacent organs may result if an IUD is left in the peritoneal cavity. Pre-operative imaging followed by laparoscopy or laparotomy is often required to remove an IUD from the peritoneal cavity.

#### 7. Expulsion

Expulsion can occur, usually during the menses and usually in the first few months after insertion. There is an increased risk of expulsion in the nulliparous patient. If unnoticed, an unintended pregnancy could occur.

#### 8. Wilson's Disease

Theoretically, ParaGard<sup>®</sup> can exacerbate Wilson's disease, a rare genetic disease affecting copper excretion.

**References:** 1. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. *Am J Obstet Gynecol.* 1992;166:1208-1213. 2. Vessey MP, Lawless M, McPherson K, Yeates D. Fertility after stopping use of intrauterine contraceptive device. *BMJ.* 1983;286:106. 3. Skjeldestad F, Bratt H. Fertility after complicated and non-complicated use of IUDs: a controlled prospective study. *Adv Contracept.* 1988;4:179-184.

### PRECAUTIONS

Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

#### 1. Information for patients

Before inserting ParaGard<sup>®</sup> discuss the Patient Package Insert with the patient, and give her time to read the information. Discuss any questions she may have concerning ParaGard<sup>®</sup> as well as other methods of contraception. Instruct her to promptly report symptoms of infection, pregnancy, or missing strings.

#### 2. Insertion precautions, continuing care, and removal.

(See Package Brochure for INSTRUCTIONS FOR USE.)

#### 3. Vaginal bleeding

In the 2 largest clinical trials with ParaGard<sup>®</sup> (see ADVERSE REACTIONS, Table 2), menstrual changes were the most common medical reason for discontinuation of ParaGard<sup>®</sup>. Discontinuation rates for pain and bleeding combined are highest in the first year of use and diminish thereafter. The percentage of women who discontinued ParaGard<sup>®</sup> because of bleeding problems or pain during these studies ranged from 11.9% in the first year to 2.2% in year 9. Women complaining of heavy vaginal bleeding should be evaluated and treated, and may need to discontinue ParaGard<sup>®</sup>. (See ADVERSE REACTIONS.)

#### 4. Vasovagal reactions, including fainting

Some women have vasovagal reactions immediately after insertion. Hence, patients should remain supine until feeling well and should be cautious when getting up.

#### 5. Expulsion following placement after a birth or abortion

ParaGard<sup>®</sup> has been placed immediately after delivery, although risk of expulsion may be higher than when ParaGard<sup>®</sup> is placed at times unrelated to delivery. However, unless done immediately postpartum, insertion should be delayed to the second postpartum month because insertion during the first postpartum month (except for immediately after delivery) has been associated with increased risk of perforation.

ParaGard<sup>®</sup> can be placed immediately after abortion, although immediate placement has a slightly higher risk of expulsion than placement at other times. Placement after second trimester abortion is associated with a higher risk of expulsion than placement after the first trimester abortion.

#### 6. Magnetic resonance imaging (MRI)

Limited data suggest that MRI at the level of 1.5 Tesla is acceptable in women using ParaGard<sup>®</sup>. One study examined the effect of MRI on the CU-7<sup>®</sup> Intrauterine Copper Contraceptive and Lippes Loop<sup>™</sup> intrauterine devices. Neither device moved under the influence of the magnetic field or heated during the spin-echo sequences usually employed for pelvic imaging. An in vitro study did not detect movement or temperature change when ParaGard<sup>®</sup> was subjected to MRI.

#### 7. Medical diathermy

Theoretically, medical (non-surgical) diathermy (short-wave and microwave heat therapy) in a patient with a metal-containing IUD may cause heat injury to the surrounding tissue. However, a small study of eight women did not detect a significant elevation of intrauterine temperature when diathermy was performed in the presence of a copper IUD.

#### 8. Pregnancy

ParaGard<sup>®</sup> is contraindicated during pregnancy. (See CONTRAINDICATIONS and WARNINGS.)

#### 9. Nursing mothers

Nursing mothers may use ParaGard<sup>®</sup>. No difference has been detected in concentration of copper in human milk before and after insertion of copper IUDs. The literature is conflicting, but limited data suggest that there may be an increased risk of perforation and expulsion if a woman is lactating.

#### 10. Pediatric use

ParaGard<sup>®</sup> is not indicated before menarche. Safety and efficacy have been established in women over 16 years old.

### ADVERSE REACTIONS

The most serious adverse events associated with intrauterine contraception are discussed in WARNINGS and PRECAUTIONS. These include:

Intrauterine pregnancy	Pelvic infection
Septic abortion	Perforation
Ectopic pregnancy	Embedment

Table 2 shows discontinuation rates from two clinical studies by adverse event and year.

Table 2. Summary of Rates (No. per 100 Subjects) by Year for Adverse Events Causing Discontinuation

Adverse Event	Year									
	1	2	3	4	5	6	7	8	9	10
Pregnancy	0.7	0.3	0.6	0.2	0.3	0.2	0.0	0.4	0.0	0.0
Expulsion	5.7	2.5	1.6	1.2	0.3	0.0	0.6	1.7	0.2	0.4
Bleeding/Pain	11.9	9.8	7.0	3.5	3.7	2.7	3.0	2.5	2.2	3.7
Other Medical Event	2.5	2.1	1.6	1.7	0.1	0.3	1.0	0.4	0.7	0.3
No. of Women at Start of Year	4932	3149	2018	1121	872	621	563	483	423	325

\*Rates were calculated by weighting the annual rates by the number of subjects starting each year for each of the Population Council (3,536 subjects) and the World Health Organization (1,396 subjects) trials.

The following adverse events have also been observed. These are listed alphabetically and not by order of frequency or severity.

Anemia	Menstrual flow, prolonged
Backache	Menstrual spotting
Dysmenorrhea	Pain and cramping
Dyspareunia	Urticarial allergic skin reaction
Expulsion, complete or partial	Vaginitis
Leukorrhea	

ParaGard<sup>®</sup> is a registered trademark of Duramed Pharmaceuticals, Inc.



DURAMED PHARMACEUTICALS, INC.  
Subsidiary of Barr Pharmaceuticals, Inc.  
Pomona, New York 10970  
Revised MAY 2006 (v.1)

## INDEX OF ADVERTISERS

<b>Archer Daniels Midland Company</b>	
Novasoy	19
<b>Berlex, Inc.</b>	
Mirena	6-8
<b>Cepheid Corporation</b>	
Xpert GBS	9
<b>Duramed Pharmaceuticals, Inc.</b> (a subsidiary of Barr Pharmaceuticals)	
Seasonique	11-14
ParaGard	25-28
<b>Genzyme Diagnostics</b>	
OSOM Tests	20
<b>Merck &amp; Co., Inc.</b>	
Gardasil	4a-4d
<b>Mission Pharmacal Company</b>	
Tindamax	21-22
<b>Novo Nordisk Inc.</b>	
Corporate	17
<b>Sanofi Pasteur Inc.</b>	
ADACEL	32a-32b
<b>Solvay Pharmaceuticals, Inc.</b>	
Prometrium	14a-14b
<b>Ther-Rx Corporation</b>	
Clindesse	22a-22b
<b>Wyeth Consumer Healthcare</b>	
Caltrate	24
<b>Wyeth Pharmaceuticals Inc.</b>	
PREMARIN Vaginal Cream	35-36